Genzyme and Isis - Top 10 deals of 2008

FierceBiotech's top 10 deals of 2008 featuring Genzyme's $1.9 million partnership with Isis PharmaceuticalsWho: Genzyme
With: Isis Pharmaceuticals
What: $1.9B partnership

Summary: Genzyme forked out a hefty $1.9 billion to partner with Isis Pharmaceuticals on development of promising cardiovascular drug mipomersen. Isis got $375 million up front. Genzyme reportedly outbid 10 other companies for rights to the drug, which blocks a gene that opens the gate to cholesterol in the blood. The drug is now in multiple Phase III trials.

Genzyme and Isis - Top 10 deals of 2008

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.